IntegraGen will oversee high-throughput sequencing activities for the National Reference Center (NRC) and microbiological collections at the Institut Pasteur.
The partnership’s primary objective, according to IntegraGen, is to increase access to next-generation sequencing technologies for the 15 NRCs and the institute’s microbiology collection. The partnership also aims to establish reference tools for the typing of bacterial, viral, and fungal strains.
Additionally,...
Dako, an Agilent Technologies company specializing in providing cancer diagnostics, said today it has again expanded a three-year-old collaboration with Amgen focused on companion diagnostics.
The value of the expanded collaboration and other financial terms were not disclosed. Dako said the expanded “multi-year” collaboration will allow both companies to benefit from knowledge-sharing within drug-diagnostic R&D, particularly in relation to companion...
Qiagen acquired AdnaGen’s circulating tumor cell (CTC) enrichment technology to boost its capabilities in liquid biopsies. Separately, the company formed a partnership with Tokai Pharmaceuticals to combine its new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai’s galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The...
Less than a month after winning its first FDA authorization, 23andMe is expanding beyond direct-to-consumer genetic testing by creating a new therapeutics group, and appointing Genentech’s recently retired evp of research and early development to lead the new unit.
Richard Scheller, Ph.D., has been named 23andMe’s CSO and head of therapeutics, effective at the beginning of next month. At the...
Tute Genomics said today a company database containing 8.5 billion annotations of genetic variants will be made publicly accessible through Google Genomics, through a partnership with Google as well as Xiaoming Liu, Ph.D., and his team at the University of Texas, Houston Health Science Center’s Human Genetics Center.
According to its main page on Google Genomics, the Tute Genomics Annotation...
Illumina said today it launched a collaboration with Merck Serono—the biopharma unit of Merck KGaA—intended to develop a universal next-generation sequencing (NGS)-based oncology diagnostic. The value of the collaboration was not disclosed.
While saying it would continue pursuing separate collaborations announced in August 2014 with AstraZeneca, Johnson & Johnson’s Janssen Biotech, and Sanofi, Illumina said it will also work with Merck...
Researchers from the Dana-Farber Cancer Institute report that websites that market personalized cancer care services often overemphasize their stated benefits and downplay their limitations. Many sites also offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to the team’s study (“Marketing of Personalized Cancer Care on the Web: an Analysis...
Advances in genomics over the past several years have had a profound impact on our grasp of molecular biology and genetics. In the laboratory, next-generation sequencing (NGS) has been applied to identifying novel genomes for an array of organisms, DNA resequencing, transcriptome sequencing, and epigenetics. Within clinical settings, NGS is beginning to cut its teeth and is being rapidly embraced as an invaluable diagnostic tool....
As mobile technology has become more powerful and ubiquitous, it was only logical to assume that health and medical apps reaching directly to the consumer could significantly change how healthcare is delivered. From applications that help patients self-monitor their diet to exercise and wellness apps, the public’s appetite for taking greater control of their health via their tablets and smartphones...
More than 1.2 million new cases of colorectal cancer (CRC) occur glob- ally each year, resulting in about 600,000 deaths. CRC remains the third most commonly diagnosed cancer in both men and women in the United States; estimated new cases in 2015 will reach 132,700.
Unfortunately, the majority of CRC cases continue to elude early detection. About 50% of CRC patients...
